TY - JOUR
T1 - Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α
AU - Cortes, Jorge E
AU - Giles, Francis
AU - O'Brien, Susan
AU - Thomas, Deborah A
AU - Garcia-Manero, Guillermo
AU - Rios, Mary Beth
AU - Faderl, Stefan H
AU - Verstovsek, Srdan
AU - Ferrajoli, Alessandra
AU - Freireich, Emil J
AU - Talpaz, Moshe
AU - Kantarjian, Hagop
PY - 2003/7/1
Y1 - 2003/7/1
N2 - Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronic-phase CML after failure on interferon-α were treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 months (range, 10-135 months); 4 patients (11%) had clonal evolution. All 11 patients with active disease achieved complete hematologic response. Excluding patients with fewer than 35% Ph-positive metaphases before the start of therapy, 19 (90%) of 21, evaluable patients achieved a major cytogenetic response. Of 27 evaluable patients, 24 (89%) achieved a complete cytogenetic response. Quantitative polymerase chain reaction was performed in bone marrow every 3 months. Of 32 evaluable patients, 18 (56%) showed BCR-ABL/ABL percentage ratios lower than 0.045%, including 13 (41%) with undetectable levels. With a median follow-up of 15 months, all patients were alive in chronic phase. Toxicities were similar to those reported with standard dose; 71% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induces complete cytogenetic responses, in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission.
AB - Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronic-phase CML after failure on interferon-α were treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 months (range, 10-135 months); 4 patients (11%) had clonal evolution. All 11 patients with active disease achieved complete hematologic response. Excluding patients with fewer than 35% Ph-positive metaphases before the start of therapy, 19 (90%) of 21, evaluable patients achieved a major cytogenetic response. Of 27 evaluable patients, 24 (89%) achieved a complete cytogenetic response. Quantitative polymerase chain reaction was performed in bone marrow every 3 months. Of 32 evaluable patients, 18 (56%) showed BCR-ABL/ABL percentage ratios lower than 0.045%, including 13 (41%) with undetectable levels. With a median follow-up of 15 months, all patients were alive in chronic phase. Toxicities were similar to those reported with standard dose; 71% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induces complete cytogenetic responses, in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission.
UR - http://www.scopus.com/inward/record.url?scp=10744231480&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744231480&partnerID=8YFLogxK
U2 - 10.1182/blood-2003-01-0025
DO - 10.1182/blood-2003-01-0025
M3 - Article
C2 - 12637317
AN - SCOPUS:10744231480
SN - 0006-4971
VL - 102
SP - 83
EP - 86
JO - Blood
JF - Blood
IS - 1
ER -